TY - JOUR
T1 - Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity
T2 - A new window into personalized medicine
AU - Bernstein, Daniel
AU - Burridge, Paul
N1 - Funding Information:
This work was supported in part by a grant from the NIH ( HL11708301 ) and from the Children's Cardiomyopathy Foundation to Dr. Bernstein and by an American Heart Association Beginning Grant-in-Aid ( 14BGIA20480329 ) and NIH Pathway to Independence Award ( K99 HL121177 ) to Dr. Burridge.
Publisher Copyright:
© 2014 Elsevier Ireland Ltd.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - In the past ten years, there has been a revolution in our ability to generate human pluripotent stem cells (hiPSCs) from adult somatic cells. hiPSCs can be differentiated into many cell types, including cardiomyocytes (hiPSC-CMs), providing cardiovascular scientists for the first time with a human heart muscle cell line. hiPSC-CMs have several potential uses: to study mechanisms of disease, as a platform for screening drugs for efficacy and toxicity, and as cell therapy for diseases such as cardiomyopathy. In this review, we discuss the potential of using hiPSC-CMs for drug toxicity testing, and in particular to screen genetic variants found to be predictive of which patients develop cardiotoxicity after receiving the chemotherapeutic agent doxorubicin.
AB - In the past ten years, there has been a revolution in our ability to generate human pluripotent stem cells (hiPSCs) from adult somatic cells. hiPSCs can be differentiated into many cell types, including cardiomyocytes (hiPSC-CMs), providing cardiovascular scientists for the first time with a human heart muscle cell line. hiPSC-CMs have several potential uses: to study mechanisms of disease, as a platform for screening drugs for efficacy and toxicity, and as cell therapy for diseases such as cardiomyopathy. In this review, we discuss the potential of using hiPSC-CMs for drug toxicity testing, and in particular to screen genetic variants found to be predictive of which patients develop cardiotoxicity after receiving the chemotherapeutic agent doxorubicin.
KW - Cancer
KW - Cardiomyocytes
KW - Doxorubicin cardiotoxicity
KW - ROS
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=84914705722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84914705722&partnerID=8YFLogxK
U2 - 10.1016/j.ppedcard.2014.10.006
DO - 10.1016/j.ppedcard.2014.10.006
M3 - Review article
C2 - 25530693
AN - SCOPUS:84914705722
VL - 37
SP - 23
EP - 27
JO - Progress in Pediatric Cardiology
JF - Progress in Pediatric Cardiology
SN - 1058-9813
IS - 1-2
ER -
